SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001558370-23-002558
Filing Date
2023-03-01
Accepted
2023-03-01 16:02:36
Documents
107
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-K imgn-20221231x10k.htm   iXBRL 10-K 2426163
2 EX-4.3 imgn-20221231xex4d3.htm EX-4.3 22131
3 EX-10.12(C) imgn-20221231xex10d12c.htm EX-10.12(C) 31992
4 EX-10.12(D) imgn-20221231xex10d12d.htm EX-10.12(D) 48561
5 EX-10.12(F) imgn-20221231xex10d12f.htm EX-10.12(F) 24979
6 EX-10.15 imgn-20221231xex10d15.htm EX-10.15 142180
7 EX-10.19 imgn-20221231xex10d19.htm EX-10.19 103629
8 EX-10.20 imgn-20221231xex10d20.htm EX-10.20 98326
9 EX-10.23 imgn-20221231xex10d23.htm EX-10.23 40770
10 EX-10.23(A) imgn-20221231xex10d23a.htm EX-10.23(A) 19518
11 EX-10.24 imgn-20221231xex10d24.htm EX-10.24 33918
12 EX-10.27 imgn-20221231xex10d27.htm EX-10.27 180270
13 EX-10.27(B) imgn-20221231xex10d27b.htm EX-10.27(B) 33580
14 EX-21 imgn-20221231xex21.htm EX-21 6064
15 EX-23 imgn-20221231xex23.htm EX-23 4715
16 EX-31.1 imgn-20221231xex31d1.htm EX-31.1 15781
17 EX-31.2 imgn-20221231xex31d2.htm EX-31.2 15867
18 EX-32 imgn-20221231xex32.htm EX-32 14389
  Complete submission text file 0001558370-23-002558.txt   11433848

Data Files

Seq Description Document Type Size
19 EX-101.SCH imgn-20221231.xsd EX-101.SCH 81250
20 EX-101.CAL imgn-20221231_cal.xml EX-101.CAL 64250
21 EX-101.DEF imgn-20221231_def.xml EX-101.DEF 383697
22 EX-101.LAB imgn-20221231_lab.xml EX-101.LAB 646540
23 EX-101.PRE imgn-20221231_pre.xml EX-101.PRE 597072
101 EXTRACTED XBRL INSTANCE DOCUMENT imgn-20221231x10k_htm.xml XML 1673499
Mailing Address 830 WINTER ST WALTHAM MA 02451
Business Address 830 WINTER ST WALTHAM MA 02451 (781)895-0600
ImmunoGen, Inc. (Filer) CIK: 0000855654 (see all company filings)

IRS No.: 042726691 | State of Incorp.: MA | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-17999 | Film No.: 23693336
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences